Researchers Prove 1st & 2nd Doses mRNA Vax Associated with Increased Myocarditis, Pericarditis

 

In a devastating new study just out and led by Dr. Øystein Karlstad and other medical professionals at the Norwegian Institute of Public Health, researchers found that the SARS-CoV-2 Vaccination showed an increased of Myocarditis and pericarditis in a Nordic Cohort Study of 23 Million Residents. Again, the first and second doses of the mRNA vax is proven to be associated with increased myocarditis/pericarditis in a study of 23 million residents.

 

Dr. Karlstad, conducted his research in the Norwegian Institute of Public Health, Department of Chronic Diseases, Department of Pharmacoepidemiology. The study was released April 20, 2022, and published in the Journal of the American Medical Association. The research reports a direct correlation between the Covid-19 vaccines causing an increase of myocarditis and pericarditis in young men aged 16 to 24 years old.

Myocarditis is an inflammation of the heart muscle (myocardium). The inflammation can reduce the heart’s ability to pump and may cause rapid or irregular heart rhythms, called arrhythmias.

 

According to the Mayo Clinic, pericarditis is swelling and irritation of the thin, saclike tissue surrounding the heart (pericardium). They say that chest pain is the most common symptom of pericarditis, but may include varied symptoms such as cough, weakness, leg swelling and many more symptoms.

 

Dr. Paul Alexander, a Canadian researcher and former administrative official at the US Department of Health and Human Services, said:

In a cohort study of 23.1 million residents across 4 Nordic countries, risk of myocarditis after the first & second doses of SARS-CoV-2 mRNA vaccines was highest in young males aged 16 to 24 years age. “Both first and second doses of mRNA vaccines were associated with increased risk of myocarditis and pericarditis.”

 

 

SOURCE: The Journal of the American Medical Association (JAMA): article entitled SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Alexander writes:

Researchers sought to examine the risks of myocarditis and pericarditis after SARS-CoV-2 injection/vaccination.

Researchers conduced 4 cohort studies and analyzed via meta-analysis. There were 23, 122, 522 residents who were 12 years or older (followed up from December 27, 2020, until incident myocarditis or pericarditis, censoring, or study end (October 5, 2021) (nationwide health registers in Denmark, Finland, Norway, and Sweden). Researchers assessed the 28-day risk periods following administration date of the 1st and 2nd doses of a SARS-CoV-2 vaccine, including BNT162b2, mRNA-1273, and AZD1222, also combinations. Measures were hospital admission for myocarditis or pericarditis.

Researchers reported that ‘among 23,122, 522 Nordic residents (81% vaccinated by study end; 50.2% female), 1077 incident myocarditis events and 1149 incident pericarditis events were identified. Within the 28-day period, for males and females 12 years or older combined who received a homologous schedule, the second dose was associated with higher risk of myocarditis, with adjusted IRRs of 1.75 (95% CI, 1.43-2.14) for BNT162b2 and 6.57 (95% CI, 4.64-9.28) for mRNA-1273. Among males 16 to 24 years of age, adjusted IRRs were 5.31 (95% CI, 3.68-7.68) for a second dose of BNT162b2 and 13.83 (95% CI, 8.08-23.68) for a second dose of mRNA-1273, and numbers of excess events were 5.55 (95% CI, 3.70-7.39) events per 100 000 vaccines after the second dose of BNT162b2 and 18.39 (9.05-27.72) events per 100 000 vaccines after the second dose of mRNA-1273. Estimates for pericarditis were similar.’

Researchers concluded that the 1st and 2nd doses of mRNA vaccines were related to elevated risk of myocarditis and pericarditis.

The association was clear. ‘For individuals receiving 2 doses of the same vaccine, risk of myocarditis was highest among young males (aged 16-24 years) after the second dose.’ These findings urge the balancing of benefits versus risks of these injections given the emerging myocarditis and pericarditis risks (that have been reported elsewhere and stably since inception of these injections).

 

Dr. Alexander is a COVID-19 Consultant Researcher in EBM, Research Methodology, and Clinical Epidemiology and he informally provides support to some members of the US Congress and Senate. Dr. Alexander recently rejected a Pfizer offer of $1 million to stop questioning COVID vaccines. He has been featured in The Standard.

 

Michael Reed is Publisher of The Standard newspaper, print and online, and TheStandardSC YouTube channel where many video reports may be found. Please share freely and donate to The Standard on this page to assure the continued availability of news that is ignored too often by the dominant media.

Please “like”, comment, share with a friend, and donate to support The Standard on this page. Become a Patron!